February 06, 2026 a 03:43 pm
CRL: Fundamental Ratio Analysis - Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. operates in a promising and essential sector of non-clinical drug development and safety testing. With a diverse service range, it supports pharmaceutical and biotechnology companies worldwide. Despite current challenges, the company's fundamental strengths offer potential for growth.
Fundamental Rating
Charles River Laboratories maintains a moderate fundamental rating. The company's performance is affected by constraints in financial metrics but continues to deliver value in key areas.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 1 | |
| Return on Assets | 1 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 3 |
Historical Rating
Recent shifts in fundamental scores show stability in certain areas but highlight the need for improvement in financial efficiency.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-02-05 | 2 | 4 | 1 | 1 | 1 | 1 | 3 |
| Previous | 0 | 4 | 1 | 1 | 1 | 1 | 3 |
Analyst Price Targets
Analyst evaluations indicate a positive outlook, with target prices reflecting potential growth in share value.
| High | Low | Median | Consensus |
|---|---|---|---|
| $260 | $185 | $215 | $214.43 |
Analyst Sentiment
The overall sentiment remains favorable, with strong buy and buy recommendations leading the consensus.
| Recommendation | Count | Proportion |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 24 | |
| Hold | 11 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Charles River Laboratories International, Inc. demonstrates resilience in its core operations despite current financial limitations. The company's strong customer base and innovative service offerings provide a foundation for potential recovery and expansion. While financial metrics are currently modest, the analyst sentiment and price targets suggest cautious optimism for future performance. Investors should consider both the growth potential and financial constraints when evaluating this stock.